Business Wire

Evolve Additive Solutions Hires Jeff Hanson as VP of Sales and Marketing

Share

Today Evolve Additive Solutions (“EAS”), a global leader in the manufacturing of capital equipment and 3D printed production AM parts, announced the appointment Jeff Hanson as the VP of Sales and Marketing. In his role Jeff will lead the go-to-market team which is comprised of sales, marketing, applications engineering, business development and product management.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005506/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jeff Hanson, VP Sales and Marketing, Evolve Additive Solutions (Photo: Business Wire)

Jeff’s experience in 3D printing and additive manufacturing technology spans over 30+ years. As one of the initial employees of Stratasys Jeff began working in early product development, obtaining three patents on Fused Deposition Modeling (FDM). Jeff Co-Founded RedEye on Demand, an industry-leading additive manufacturing parts provider business. Additionally, he innovated and led the management of Global Manufacturing Network, a cloud connected manufacturing solution with global strategic partners in international markets. Most recently he founded Digital 3D Manufacturing, LLC, which provides consultative services on the adoption of additive manufacturing solutions to the global manufacturing market.

“It is an exciting time for Evolve and the company’s STEP technology and I am confident that this platform with change the way traditional manufacturing is perceived,” said Hanson. “I’m certain that my background and leadership along with this outstanding team will all work together to ensure our growth.”

“Having a true industry expert join Evolve is an asset to us,“ said Joe Allison, CEO of Evolve Additive Solutions. “Jeff’s expertise in startups and high growth environments is critical to our future success.”

Evolve’s STEP (selective thermoplastic electrophotographic process) technology sits alongside traditional manufacturing processes, such as injection molding, on the manufacturing floor and augments an organization’s production capabilities allowing freedom of design and faster time to market with “toolless” production. Evolve’s ecosystem and products and services includes hardware, software, materials, services and applications consulting.

About Evolve Additive Solutions

Evolve Additive Solutions is transforming how the world manufactures. Founded in 2017, the company offers Additive Manufacturing production equipment, materials, software, service, consulting and application services. Evolve allows for manufacturing flexibility, creating uniquely functional products while increasing speed to market and efficiency securing supply chains. Evolve’s patented STEP (selective thermoplastic electrophotographic process) technology is able to efficiently produce commercial grade production parts and create unique products that cannot be manufactured with traditional methods. The company is headquartered in Minnetonka, MN with a materials technology center based in Rochester, NY.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cheryl Hillman, Evolve Additive Solutions
763-438-6569 cheryl.hillman@evolveadditive.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SK pharmteco and LOTTE BIOLOGICS Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities29.10.2025 16:35:00 EET | Press release

SK pharmteco and LOTTE BIOLOGICS have announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029483889/en/ Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco. Through this collaboration, the two companies will jointly investigate prov

Phenom Named Strategic Leader in 2025 Fosway 9-Grid™ for Talent & People Success for Second Consecutive Year29.10.2025 15:30:00 EET | Press release

Phenom, an applied AI company that helps organizations hire faster, develop better and retain longer, has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029195746/en/ Phenom has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. Fosway Group identifies Strategic Leaders as companies that provide a ric

Andersen Consulting Adds Collaborating Firm Vivaldi29.10.2025 15:30:00 EET | Press release

Andersen Consulting announces a Collaboration Agreement with Vivaldi, a global business and brand strategy consultancy, strengthening the organization’s strategy and business transformation offerings. Founded in 1999, Vivaldi is known for its approach to converge brand, business, and technology to keep clients in their leadership position. Operating in the U.S., Europe, and Latin America, Vivaldi works with leading global companies to build strong market positions, accelerate innovation, and design customer-centric business models. In today’s fast-evolving world shaped by AI, platform dynamics, and continuous reinvention, Vivaldi helps clients reimagine how business value is created and captured. The firm’s multidisciplinary teams blend deep consumer insight and market foresight with strategic, creative, and financial rigor to deliver tailored solutions for growth, transformation, and long-term competitiveness across industries. “Today’s business landscape demands that organizations le

Ferring Pharmaceuticals to Explore Strategic Options for Rebyota ®29.10.2025 15:00:00 EET | Press release

As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live – jslm). To date, more than five thousand patients suffering from recurrent Clostridioides difficile infection (rCDI) have found new hope when treated with Rebyota®. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continued commercialisation. As a result, Ferring will reduce commercial efforts in the United States while ensuring uninterrupted access for patients. Approved by the U.S. Food and Drug Administration (FDA) in 2022, Rebyota® was the first FDA-approved faecal microbiota transplant, indicated for the prevention of rCDI in adults following antibiotic treatment for recurrent CDI. This milestone marked a significant advancement in understanding the role of the human microbiome in health and disease. Ferring

GigaDevice GD32F5xx and GD32G5xx Software Test Libraries (STL) Receive TÜV Rheinland IEC 61508 Functional Safety Certification29.10.2025 15:00:00 EET | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced that its GD32F5xx and GD32G5xx Software Test Libraries have received IEC 61508 SC3 (SIL 2/SIL 3) functional safety certification from TÜV Rheinland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029124621/en/ Certificate This milestone expands GigaDevice’s functional safety portfolio, which already includes the GD32H7 and GD32F30x STLs, and now covers a broad range of MCUs with Arm® Cortex®-M7, Cortex®-M4, and Cortex®-M33 cores. Building on this foundation, GigaDevice will continue to deliver high-performance and safety-focused hardware and software solutions for key applications such as industrial control, energy and power, and humanoid robotics. With the growing emphasis on safety across industries like industrial automation, functional safety has become a critical considerat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye